Premium
Septic neonate rescued by p olymyxin B hemoperfusion
Author(s) -
Hirakawa Eiji,
Ibara Satoshi,
Tokuhisa Takuya,
Hiwatashi Sayuri,
Hayashida Yoshihiro,
Maede Yoshinobu,
Matsui Takako,
Nakazawa Yusuke,
Inoue Takeshi,
Kodaira Yuichi
Publication year - 2013
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1111/ped.12029
Subject(s) - hemoperfusion , medicine , polymyxin b , septic shock , sepsis , polymyxin , microbiology and biotechnology , antibiotics , pharmacology , anesthesia , immunology , biology , hemodialysis
Sepsis caused by g roup B streptococcus has been well controlled with aminobenzylpenicillin, but the incidence of E scherichia coli sepsis has increased in proportion. E. coli is a G ram‐negative bacillus associated with poor prognosis due to the release of endotoxins. Conventional treatment with antibiotics alone may not be sufficient because the inflammatory response exacerbates the unstable hemodynamic status. Polymyxin B hemoperfusion has been established as a treatment option for septic shock in adults. Polymyxin B hemoperfusion adsorbs endotoxins and cannabinoids such as anandamide and 2‐arachidonoylglycerol. Reported herein is a case of severe septic shock induced by E . coli . The concomitant use of polymyxin B hemoperfusion rapidly reduced the requirement for catecholamines and the patient was discharged without short‐term neurological or respiratory sequelae. It is suggested that polymyxin B hemoperfusion might be an innovative therapy for severe sepsis, and could improve outcome.